Mark J. Ratain to Taxoids
This is a "connection" page, showing publications Mark J. Ratain has written about Taxoids.
Connection Strength
0.716
-
Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors. Med Oncol. 2003; 20(1):7-12.
Score: 0.204
-
Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs. 2001 May; 19(2):171-7.
Score: 0.182
-
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. Clin Cancer Res. 2016 Oct 01; 22(19):4890-4900.
Score: 0.129
-
The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenet Genomics. 2013 Jan; 23(1):29-33.
Score: 0.102
-
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clin Cancer Res. 2007 Jun 01; 13(11):3302-11.
Score: 0.069
-
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer. 2015 Apr 01; 121(7):1025-31.
Score: 0.029